Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

Insiders have been trading these 5 stocks: (($GD)), (($TMO)), (($CVNA)), (($BIIB)) and (($SCHW)). Here is a breakdown of their recent trades and th...

Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen extends study of kidney rejection drug felzartamab This long-term e...

Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen today and set a price target of $241.00. Syed covers the Healthcare sector, ...

Mizuho Securities Keeps Their Buy Rating on Biogen (BIIB)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $242.00. According to TipRanks, Matteis is a...

Stifel Nicolaus Remains a Buy on Biogen (BIIB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB), Teladoc (TDOC) and Damora Therapeut...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Teladoc (TDOC) and Damora Therapeutics (DMRA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Xencor (XNCR) with bullish sentime...

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Xencor (XNCR)

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen, with a price target of $201.00. Chico covers the Healthcar...

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $200.00. Field covers the Healthca...

Barclays Sticks to Its Hold Rating for Biogen (BIIB)

Piper Sandler analyst David Amsellem maintained a Buy rating on Biogen today and set a price target of $225.00. According to TipRanks, Amsellem is ...

Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB)

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has launched a Phase 1 study called “A Phase 1, Randomi...

Biogen’s BIIB144 First‑in‑Human Trial: What Early Safety Data Could Mean for BIIB Investors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALN...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALNY) and Biogen (BIIB)

Analysts are intrested in these 5 stocks: ( ($BIIB) ), ( ($BE) ), ( ($FSLR) ), ( ($OKLO) ) and ( ($NNE) ). Here is a breakdown of their recent


Biogen, Bloom, First Solar, Oklo, NNE Trending With Analysts

With markets continuing to be volatile, some stocks are drawing attention for their solid fundamentals and rising analyst confidence. TipRanks’ Tre...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$209.83	-0.39%	554.42K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$209.83	-0.4%	554.42K
3
4
5
6

BIIB

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel